Effects of Acetazolamide and CO2 Inhalation on Exercise-Induced Periodic Breathing in Heart Failure

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2007 by Centro Cardiologico Monzino.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Centro Cardiologico Monzino
ClinicalTrials.gov Identifier:
NCT00517426
First received: August 16, 2007
Last updated: NA
Last verified: August 2007
History: No changes posted

August 16, 2007
August 16, 2007
July 2007
Not Provided
Suppression of periodic breathing [ Time Frame: two days ]
Same as current
No Changes Posted
suppression of sleeping apnea [ Time Frame: two days ]
Same as current
Not Provided
Not Provided
 
Effects of Acetazolamide and CO2 Inhalation on Exercise-Induced Periodic Breathing in Heart Failure
Not Provided

To evaluate the effects of CO2 inhalation and acetazolamide treatment on exercise-induced periodic breathing in patients with chronic stable heart failure.

Patients will be given CO2 (2%) during a constant workload exercise. Patients will be also evaluated by maximal cardiopulmonary exercise test without and with acetazolamide acute and chronic treatment.

Not Provided
Interventional
Phase 4
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Chronic Heart Failure
Drug: acetazolamide
i.v. 500 mg of acetazolamide for the acute study and 500 mg of acetazolamide p.o. t.i.d. for two days
Other Name: Diamox
Not Provided
Agostoni P, Bussotti M, Cattadori G, Margutti E, Contini M, Muratori M, Marenzi G, Fiorentini C. Gas diffusion and alveolar-capillary unit in chronic heart failure. Eur Heart J. 2006 Nov;27(21):2538-43. Epub 2006 Oct 6.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
20
August 2009
Not Provided

Inclusion Criteria:

  • chronic heart failure in stable clinical condition
  • exercise-induced periodic breathing

Exclusion Criteria:

  • comorbidities
  • NYHA class IV
Both
18 Years to 80 Years
No
Contact: Piergiuseppe Agostoni, MD, PhD +39.025800 ext 2299 piergiuseppe.agostoni@ccfm.it
Italy
 
NCT00517426
R77-CCM S79/407
No
Not Provided
Centro Cardiologico Monzino
Not Provided
Principal Investigator: Piergiuseppe Agostoni, MD, PhD Centro Cardiologico Monzino
Centro Cardiologico Monzino
August 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP